|
000
| 02831nam 2200361zi 4500 |
|---|
| 001 | 9.895302 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107174004 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 210114s1965 onc obs f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | |aZ1-1961/3-1-7E-PDF|zZ1-1961/3-1/7 |
|---|
| 110 | 1 |aCanada. |bDepartment of National Health and Welfare. |bResearch and Statistics Division, |eauthor. |
|---|
| 245 | 10|aProvision, distribution, and cost of drugs in Canada / |cResearch and Statistics Division, Department of National Health and Welfare. |
|---|
| 264 | 1|aOttawa, Canada : |bRoger Duhamel, Queen's Printer and Controller of Stationery, |c1965. |
|---|
| 300 | |a1 online resource (viii, 128 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aDigitized edition from print [produced by Privy Council Office]. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 505 | 0 |aForeword -- List of Tables -- Introduction -- Background of Canadian Pharmacy -- Present Methods of Production and Distribution of Drugs in Canada -- Expenditure on Drugs in Canada -- Pharmaceutical Benefits for Recipients of Organized Public Assistance Programs in Canada -- Voluntary Prepayment Plans -- Provision of Drugs Under Health Insurance Programs in Various Countries -- Appendix. |
|---|
| 520 | |a"During the past four years the entire spectrum of costs, profits and prices of drugs has been intensively discussed by the Canadian public. The first formal investigation of recent importance on this continent was that undertaken in the United States by the Senate Subcommittee on Antitrust and Monopoly (the Kefauver Committee). This committee's inquiry was followed in Canada by the investigation on the manufacture, distribution and sale of drugs undertaken by the Director of Investigation and Research under the Combines Investigation Act. His study was, in turn, followed by hearings initiated by the Federal Restrictive Trade Practices Commission to ascertain whether or not price-fixing of drugs exists at any, or all three, of the manufacturing, distributing and retailing levels. The primary aim has been to include constructive and factual information derived from objective evidence within the Canadian context"--Introduction. |
|---|
| 650 | 0|aPharmaceutical industry|zCanada. |
|---|
| 650 | 0|aDrugs|xPrices|zCanada. |
|---|
| 650 | 6|aIndustrie pharmaceutique|zCanada. |
|---|
| 650 | 6|aMédicaments|xPrix|zCanada. |
|---|
| 655 | 7|aStatistics|2lcgft |
|---|
| 655 | 7|aStatistiques|2rvmgf |
|---|
| 710 | 1 |aCanada.|bRoyal Commission on Health Services, |eissuing body. |
|---|
| 856 | 40|qPDF|s53.07 MB|uhttps://publications.gc.ca/collections/collection_2021/bcp-pco/Z1-1961-3-1/Z1-1961-3-1-7-eng.pdf |
|---|